-
-
-
-
-
-
-
Mereo BioPharma Sends Letter to Rubric Capital Management
-
-
-
-
-
-
-
Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
-
-
-
-
-
-
-
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
-
-
-
-
-
-
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
-
-
-
-
-
-
-
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
-
-
-
-
-
-
-
Mereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress
-
-
-
-
-
-
-
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
-
1,160,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

